Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
AB-101
product2 mentionslast seen Nov 12, 2026
Oral PD-L1 inhibitor for chronic hepatitis B virus infection.
Relationships 5
- Arbutus Biopharma CorporationdevelopsAB-10199% confidence2 sources
- AB-101depends onPD-L1 inhibition95% confidence1 source
- U.S. Food and Drug AdministrationapprovesAB-10195% confidence1 source
- AB-101applies tochronic hepatitis B virus infection treatment92% confidence1 source
- AB-101applies tochronic hepatitis B treatment90% confidence1 source
Relationship
Arbutus Biopharma CorporationdevelopsAB-101
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 12, 2026Arbutus Biopharma Corp 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
AB - 101 Small Molecule PD - L1 Inhibitor (Oral) Immunotherapy Program
- filingSEC EDGAROct 22, 2026Arbutus Biopharma Corp 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
the Company may engage in additional clinical development for AB-101